The CRU combines and exploits internationally renowned expertise in podocyte research at the University Hospital of Cologne and basic science expertise at the Faculty of Natural Sciences of the University of Cologne, all located within walking distance on a single life science campus. We are convinced that this approach will ultimately result in practice-changing research, leading to improved diagnostics and tailored new treatment options that allow individualized treatment strategies in podocyte disorders not only limited to FSGS.
The CRU 329 was established in April 2018 and is organized into 8 scientific and 3 central projects. The speaker of the CRU is Professor Thomas Benzing, director of the Department II of Internal Medicine (Divisions of Nephrology, Rheumatology, Diabetes and General Internal Medicine) of the University Hospital of Cologne. The scientific coordinator of the CRU is Professor Paul Brinkkoetter, Department II of Internal Medicine of the University Hospital of Cologne.